Rapid resistance profiling of SARS-CoV-2 protease inhibitors

Mostrar otras versiones (1)

Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghadasi, Seyed Arad, Biswas, Rayhan G., Harki, Daniel A., Harris, Reuben S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002627/
https://www.ncbi.nlm.nih.gov/pubmed/36909573
http://dx.doi.org/10.1101/2023.02.25.530000
Descripción
Sumario:Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms (“fingerprints”) and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa.

Ejemplares similares